1. Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962;De Vita;Cancer Res,1965
2. Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037);Hansen;Cancer Res,1971
3. Fiebig HH, Henz H, Arnold H, Schuchhardt C, Eisenbrand G, Lohr GW. Phase I clinical evaluation of the new watersoluble nitrosourea HECNU. Eur J Cancer (in press).
4. Hartley-Asp B, Christensson P-I, Gunnarsson K, Gunnarsson PO, Polacek J, Stamvik A. Anti-tumour, toxicological and pharmacokinetic properties of a novel taurine-linked nitrosourea (TCNU). New Invest Drugs (submitted for publication).
5. Roed H, Vindeløv LL, Spang-Thomsen M, Chistensen IJ, Hansen HH. In vitro evaluation of a new nitrosourea, TCNU, against human small cell lung cancer cell lines. Cancer Chemother Pharmacol (submitted for publication).